Creative Planning increased its position in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT – Free Report) by 34.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 28,529 shares of the company’s stock after purchasing an additional 7,297 shares during the period. Creative Planning’s holdings in Adaptive Biotechnologies were worth $191,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently modified their holdings of ADPT. Point72 Middle East FZE acquired a new position in shares of Adaptive Biotechnologies during the fourth quarter worth $26,000. Meeder Asset Management Inc. lifted its stake in Adaptive Biotechnologies by 407.8% during the fourth quarter. Meeder Asset Management Inc. now owns 5,632 shares of the company’s stock worth $43,000 after purchasing an additional 4,523 shares during the last quarter. PNC Financial Services Group Inc. lifted its stake in Adaptive Biotechnologies by 176.7% during the first quarter. PNC Financial Services Group Inc. now owns 5,293 shares of the company’s stock worth $73,000 after purchasing an additional 3,380 shares during the last quarter. Townsquare Capital LLC purchased a new stake in Adaptive Biotechnologies during the fourth quarter worth approximately $81,000. Finally, NewEdge Advisors LLC lifted its stake in Adaptive Biotechnologies by 456.4% during the first quarter. NewEdge Advisors LLC now owns 12,230 shares of the company’s stock worth $84,000 after purchasing an additional 10,032 shares during the last quarter. Institutional investors and hedge funds own 94.31% of the company’s stock.
Insider Buying and Selling at Adaptive Biotechnologies
In other Adaptive Biotechnologies news, insider Nitin Sood sold 5,652 shares of the business’s stock in a transaction on Monday, August 7th. The shares were sold at an average price of $6.78, for a total value of $38,320.56. Following the transaction, the insider now directly owns 225,358 shares of the company’s stock, valued at approximately $1,527,927.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 5.20% of the stock is owned by company insiders.
Analyst Upgrades and Downgrades
Get Our Latest Stock Analysis on Adaptive Biotechnologies
Adaptive Biotechnologies Stock Down 8.7 %
NASDAQ:ADPT opened at $4.28 on Thursday. The company has a market capitalization of $619.10 million, a PE ratio of -3.22 and a beta of 1.25. The stock’s 50 day moving average price is $5.53 and its 200 day moving average price is $6.67. Adaptive Biotechnologies Co. has a 52-week low of $3.94 and a 52-week high of $10.79.
Adaptive Biotechnologies (NASDAQ:ADPT – Get Free Report) last issued its quarterly earnings results on Wednesday, August 2nd. The company reported ($0.33) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.33). The firm had revenue of $48.93 million during the quarter, compared to analysts’ expectations of $44.87 million. Adaptive Biotechnologies had a negative net margin of 100.69% and a negative return on equity of 43.10%. Adaptive Biotechnologies’s quarterly revenue was up 12.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.37) EPS. As a group, sell-side analysts anticipate that Adaptive Biotechnologies Co. will post -1.21 EPS for the current fiscal year.
Adaptive Biotechnologies Profile
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals.
Featured Stories
- Five stocks we like better than Adaptive Biotechnologies
- Manufacturing Stocks Investing
- The top 3 stocks insiders are selling, but you shouldn’t
- What is the NASDAQ Stock Exchange?
- Spirit AeroSystems Goes Airborne After Inking a Boeing Deal
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Simon Property Group’s 7.2% Dividend Has Insiders Buying In Bulk
Receive News & Ratings for Adaptive Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptive Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.
